Severe Breakthrough COVID-19 in CAR T-cell treated patient

A 51-year-old woman, with anemia and rib fractures, diagnosed with IgG-kappa multiple myeloma (MM) in 2012, initially achieved complete remission. However, in 2020, she experienced a clinical relapse followed by a biochemical relapse. In 2021, she received two doses of the mRNA vaccine BNT162b2 against SARS-CoV-2, yielding no serological response. Subsequently, before undergoing CAR T-cell therapy, she received a third vaccine boost in March. Two months later, in July 2022, she contracted a SARS-CoV-2 infection, presenting with a dry cough and low-grade fever.

Due to relapsed/refractory multiple myeloma (R/R MM), the patient underwent various treatments, including CAR T-cell therapy. Despite achieving minimal residual disease negativity post-infusion, she developed severe COVID-19 pneumonia, posing challenges to her clinical management.  Her prolonged hospitalization was marked by a complex interplay of factors: pulmonary embolism, immune deficiencies including B-cell aplasia and lymphocyte subpopulation deficits, and secondary infections like pulmonary aspergillosis. 

Despite antiviral therapy with molnupiravir, her cough worsened, and a CT scan on admission revealed bilateral interstitial pneumonia. Blood tests indicated lymphopenia (800 cells/µl), hypogammaglobulinemia (200 mg/dl), and elevated inflammatory markers (CRP 38,000 µgr/l and IL-6 38 pg/ml). Standard treatments like remdesivir and tixagevimab-cilgavimab failed to improve her clinical condition, exacerbated by pulmonary embolism, necessitating high-flow oxygen therapy. Viral genotyping identified a non-BA.2 omicron variant with positive viremia, and antinucleocapsid antibodies were not detected. Hyperimmune plasma infusion gradually resolved opacities, improving respiratory failure. Subsequently, pulmonary aspergillosis emerged and was successfully treated with a two-month course of isavuconazole. Intravenous immunoglobulin G therapy (IVIG) at 400 mg/kg weekly, during antifungal treatment, aimed to reach normal IgG levels (≥ 700 mg/dl). SARS-CoV-2 clearance was achieved in December 2022, leading to the patient's discharge after a five-month hospitalization.

Optimal therapeutic strategies against COVID-19 in immunocompromised patients remain poorly understood. Combined treatments, such as passive immunotherapy (convalescent plasma and/or monoclonal antibodies) and antivirals, show promise in B-cell-depleted patients. Careful monitoring of immune reconstitution post-CAR T-cell therapy is crucial in the hematological population, necessitating further investigations to identify tailored therapeutic strategies against COVID-19.


REFERENCE

Ielo C, Fazio F, Rocchi S, Rizzello I, Mancuso K, Zamagni E, Cavo M, Petrucci MT. Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight. Leuk Res Rep. 2023 Nov 27;21:100399. doi: 10.1016/j.lrr.2023.100399. PMID: 38078287; PMCID: PMC10698652.


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more